ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Filgrastim

Also written as “filgrastim”, “Neupogen (filgrastim)” and “Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous”.

Its studies are mostly in Neutropenia · Breast Neoplasms · ST Elevation Myocardial Infarction · Multiple Myeloma · Lymphoma, Non-Hodgkin, led by 15 companies.

Drug pageFilgrastim: every studyMany companies study it; this page follows only the 27 they lead. All 304 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 2, 199927 company-led studies, 1 open or runningNext primary completion: Apr 7, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen50 open or runningphase 2since Nov 2, 1999Nov 2, 1999none ahead
Pfizerits history only50 open or runningphase 2since Nov 5, 2013Nov 5, 2013none ahead
Biocadits history only30 open or runningphase 3since Apr 2, 2014Mar 30, 2012none ahead
Dong-A STits history only20 open or runningphase 3since Nov 10, 2017Mar 22, 2016none ahead
Novartisits history only20 open or runningphase 4since May 8, 2013Jan 13, 2012none ahead
Axaron Bioscienceits history only10 open or runningphase 2since Aug 18, 2005Aug 18, 2005none ahead
Azidus Brasilits history only10 open or runningphase 1since Mar 6, 2012Mar 6, 2012none ahead
BioGeneric Pharmaits history only11 open or runningphase 1since Oct 4, 2026Oct 4, 2026Apr 7, 2027phase 1 · NCT07877467
Clinique Ovoits history only10 open or runningphase 3since Mar 19, 2014Mar 19, 2014none ahead
CSLits history only10 open or runningphase 1since May 31, 2019May 31, 2019none ahead

Also a collaborator on its studies: Celerion, Sandoz and Numoda.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Amgen only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 2, 1999First study: phase 2 study in HIV InfectionsFirst studyNCT00002126 · 250 enrolled · United States, Canada
  2. Jul 5, 2000Phase 2 study in Urinary Bladder NeoplasmsNCT00005958 · United States
  3. Sep 11, 2000Phase 2 study in Lung NeoplasmsNCT00006215 · United States
  4. Jun 30, 20052 phase 2 studies in Lymphoma, Non-HodgkinNCT00117897, NCT00117455

TargetBeta

CSF3R →read by rule
“Granulocyte colony stimulating factor receptor agonist”ChEMBL 37, by rule

Other programs on CSF3R

ProgramCompanyFurthest phaseStudies
pegfilgrastimruleAmgenphase 452
anumigilimabruleCSLphase 24

Studies

All 5 Amgen leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00117897Lymphoma, Non-Hodgkin2Completed
NCT00117455Lymphoma, Non-Hodgkin2Completed
NCT00006215Lung Neoplasms · United States2UNKNOWN
NCT00005958Urinary Bladder Neoplasms · United States2UNKNOWN
NCT00002126HIV Infections · United States, Canada2Completed250

How it is read

Names in the registry

  • “Filgrastim”, 11 entries
  • “filgrastim”, 4 entries
  • “Neupogen (filgrastim)”, 2 entries
  • “Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous”, 2 entries
  • “Leucostim®”, 2 entries

Codes read as this program: DA3030.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.